Study #2016-0316
A Phase 1/2 Multi-Center Study Evaluating the Safetyand Efficacy of KTE-X19 in Pediatric and AdolescentSubjects with Relapsed/Refractory B-precursor AcuteLymphoblastic Leukemia or Relapsed/Refractory B-CellNon-Hodgkin Lymphoma (ZUMA-4)
MD Anderson Study Status
Enrolling
Treatment Agent
Brexucabtagene Autoleucel (KTE-X19), Fludarabine, Cyclophosphamide
Description
The primary objectives of this study are to evaluate the safety and efficacy of brexucabtagene autoleucel (KTE-X19) in pediatric and adolescent participants with relapsed/refractory (r/r) B-precursor acute lymphoblastic leukemia (ALL) or relapsed or refractory (r/r) B-cell non-Hodgkin lymphoma (NHL).
Information and next steps
Disease:
Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia, Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Study phase:
I/II
Physician name:
Sajad Khazal
Department:
Pediatrics
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.